Sort
23,748 grants matching “melanoma”
Gene therapy of cancer
$2,622,375Steven Rosenberg · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Adoptive Cell Transfer Immunotherapy of Cancer
$2,622,375Steven Rosenberg · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Infections, immunity, and inflammation in cancer
$2,614,752Eric A Engels · Division Of Cancer Epidemiology And Genetics · ZIA · FY2025 · CA
Allogeneic Immunotherapy for cancer and nonmalignant hematological disorders
$2,610,373Richard Childs · National Heart, Lung, And Blood Institute · ZIA · FY2013 · HL
Allogeneic Immunotherapy for cancer and nonmalignant hematological disorders
$2,609,499Richard Childs · National Heart, Lung, And Blood Institute · ZIA · FY2012 · HL
Combination Therapies to Defeat Melanoma Resistance
$2,608,967Antoni Ribas · University Of California Los Angeles · P01 · FY2021 · CA
The Center for Tumor-Immune Systems Biology at MSKCC
$2,601,900Christina S Leslie · Sloan-Kettering Inst Can Research · U54 · FY2023 · CA
Role of microbiome in cancer and inflammation
$2,596,550Giorgio Trinchieri · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
CONSOLIDATED BASIC CANCER RESEARCH PROGRAM
$2,595,926Russel E. Kaufman · Wistar Institute · P30 · FY2006 · CA
Depleting S1P to reverse immune exclusion for effective cancer immunotherapy
$2,592,085Everett Stone · University Of Texas At Austin · R01 · FY2025 · CA
DNA Sequencing and FACS Core Facilities
$2,587,962Paul Robbins · Division Of Basic Sciences - Nci · ZIC · FY2020 · CA
Nanosystems Biology Cancer Center 2
$2,586,441James R. Heath · California Institute Of Technology · U54 · FY2010 · CA
Consolidated Basic Cancer Research Program
$2,578,347Dario C. Altieri · Wistar Institute · P30 · FY2015 · CA
Combination Therapies to Defeat Melanoma Resistance
$2,574,738Antoni Ribas · University Of California Los Angeles · P01 · FY2020 · CA
Repository Services for epidemiology studies
$2,574,308David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2012 · CA
An integrative approach to target lineage-specific oncogenic transcription factor
$2,569,500Ping Chi · Sloan-Kettering Inst Can Research · DP2 · FY2012 · CA
Targeted Therapies in Melanoma
$2,567,345Meenhard Herlyn · Wistar Institute · P01 · FY2013 · CA
Defining Melanoma Therapeutic Avenues by Integrative Functional Genomics
$2,565,000Levi Alexander Garraway · Dana-Farber Cancer Inst · DP2 · FY2007 · OD
Spatiotemporal Tumor Analytics for Guiding Sequential Targeted-Inhibitor: Immunotherapy Combinations (ST-Analytics)
$2,564,339James R. Heath · Institute For Systems Biology · U54 · FY2025 · CA
Molecular Assays for epidemiology studies
$2,561,365David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2013 · CA
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders
$2,561,153Richard Childs · National Heart, Lung, And Blood Institute · ZIA · FY2015 · HL
Combination Therapies to Defeat Melanoma Resistance
$2,556,789Antoni Ribas · University Of California Los Angeles · P01 · FY2023 · CA
Combination Therapies to Defeat Melanoma Resistance
$2,556,789Antoni Ribas · University Of California Los Angeles · P01 · FY2022 · CA
DNA Sequencing and FACS Core Facilities
$2,549,754Paul Robbins · Division Of Basic Sciences - Nci · ZIC · FY2022 · CA
Cancer Center Support Grant
$2,549,235Benjamin G. Neel · New York University School Of Medicine · P30 · FY2016 · CA